decisionhealth Newsletters, Part B News - 2023 Issue 3 (March)
Some drugs with co-insurance cuts have low usage, high denials
Subscribe or sign in to view the full article.
Article Overview
This premium article examines a Medicare Part B drug benchmark tied to reduced co-insurance drugs in the 2nd quarter of 2023. It focuses on utilization patterns, denial experience, and broader ASP drug pricing trends using Medicare claims data and CMS-referenced drug lists. The piece is aimed at coders, billing professionals, and reimbursement analysts who need a high-level view of which drug categories are affected and how the article frames their relative impact.
Why This Topic Matters
It helps readers understand where reduced Part B drug co-insurance intersects with utilization and denial patterns, and how those drugs compare with the broader Medicare drug payment landscape.
Article Sections
-
Benchmark of the week
Overview of the benchmark topic and the Medicare Part B drug context for the period discussed. Introduces the article’s focus on utilization, pricing, and co-insurance changes.
What You Will Learn
- How the article frames reduced co-insurance changes in the Medicare Part B drug setting
- What broad utilization and denial patterns are highlighted in relation to selected drugs
- How the article compares the benchmark drugs with overall ASP drug pricing trends
- Which general data sources are referenced for the analysis
Who Should Read This
- Medical coders
- Billing specialists
- Reimbursement analysts
- Healthcare finance professionals
- Medicare-focused revenue cycle staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com